Acarix Ab (ACIXF)

$0.03 0.00 (-3.55%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100,000
Avg Vol 131,502
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 40%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.

Industry: Medical Devices
Sector: Healthcare
Address:
Regus MalmOe, Hyllie Boulevard 34, 5TR, Malmö, Sweden
Pandurotwo
Pandurotwo Apr. 9 at 7:02 PM
$ACIXF https://iqmediacorp.com/ExternalIframeMedia?mediaID=41fb0f68-a9ca-4f8f-bf3f-3d8597280833&isRM=false&rawMediaType=TV&end=true
0 · Reply
Pandurotwo
Pandurotwo Apr. 9 at 6:59 PM
$ACIXF From LinkedIn Dr. George Chrysant and I sat down with KOKH FOX 25 News, Oklahoma to discuss new research from the American Heart Association, and the implications are far bigger than many realize. By 2050, 6 in 10 U.S. women are projected to have some form of cardiovascular disease. At the same time, rates of diabetes and obesity in women are expected to rise by 67% and 36%, respectively. Even more concerning, cardiovascular disease is accelerating among younger populations, impacting nearly a third of women ages 20–44 and rising sharply among girls. This isn’t just a women’s health issue. It’s a public health issue that affects families, communities, and the future of our healthcare system. Despite being the leading cause of death for women, heart disease is still too often underdiagnosed, especially when symptoms don’t present in typical ways. That gap in awareness, detection, and access to care is something we must address now. At Acarix, we believe earlier insight
1 · Reply
Pandurotwo
Pandurotwo Mar. 29 at 7:17 PM
$ACIXF From the CEO: Great to spend time at #ACC with Ken Nelson, whose experience and perspective continue to be incredibly valuable as we scale Acarix in the U.S. and beyond. What stands out most is the convergence we are seeing across the ecosystem. Conversations with customers, partners, and industry leaders are no longer siloed. Commercial strategy, R&D innovation, and collaborative partnerships are aligning in a very real way. From a commercial standpoint, there is growing clarity around how #CADScor can be integrated into clinical workflows to drive better patient outcomes while reducing unnecessary testing. That alignment is critical as we continue to expand access and….
2 · Reply
Pandurotwo
Pandurotwo Mar. 13 at 11:56 AM
$ACIXF Article from 10th March 2026. European Heart Journal. See attached. https://academic.oup.com/ehjimp/advance-article/doi/10.1093/ehjimp/qyag043/8512988 Article Navigation JOURNAL ARTICLE ACCEPTED MANUSCRIPT Diagnostic performance of combined biomarkers and phonocardiography versus the 2024 ESC risk factor-weighted clinical likelihood model for detecting coronary artery disease
0 · Reply
Pandurotwo
Pandurotwo Oct. 9 at 3:39 PM
$ACIXF Today Oct. 9th: NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB Qoute: Proposed agenda Opening of the general meeting and election of chairman of the general meeting Preparation and approval of the voting list Election of one or two persons to verify the minutes Approval of the agenda Determination as to whether the meeting has been duly convened Resolution to change the terms in the Employee Stock Option Program 2025/2029 Closing of the general meeting. Unqoute. Nothing changes for us. In short: "Resolution to change the terms in the Employee Stock Option Program 2025/2029" , " Dilution No change in dilution will arise as a result of the board's proposed amendments.".
0 · Reply
Pandurotwo
Pandurotwo Oct. 8 at 1:28 PM
$ACIXF Good News! When searching the swedish finansiel register the net short position of all outstanding short positions has dropped below the min. reporting limit. (This time the shorters lost money on their inventure, ( approx. 15%)).
0 · Reply
Pandurotwo
Pandurotwo Oct. 7 at 9:53 AM
$ACIXF New reembursement deal in place.
0 · Reply
Pandurotwo
Pandurotwo Oct. 6 at 6:20 PM
$ACIXF The German reimbursement for medical devices with regards to Acarix CADScor will be settled when the 13 members of the Federal Joint Committee have their monthly sitdown on October 16th 11am to 3pm lt in Berlin, Germany. Under TOP 8 , topic): 8.3.2 and 8.3.3 Guideline on Methods of Statutory Health Care: Phonocardiography to rule out coronary heart disease In order to decide on an amendment to the MVV-RL & KHMe-RL directive. At this point I can’t find anything on the amount of reimbursement as there is some variables which the G-BA will uncover on 16th. It is certain though that reimbursement depends on inclusion in specific service catalogues or as assistive devices listed in the Medical Aids Directory.
0 · Reply
Pandurotwo
Pandurotwo Sep. 18 at 6:09 PM
$ACIXF Notice. We know the CEO increased his stock by 1 mill. to 10,904,824 shares and 50,000,000 stock options 10 days ago. 18th Sept.: "Acarix Chairman Jan Poulsen Acquires Shares I the period 15. -- 18. September, Jan Poulsen privately purchased 475,000 shares at an average price of SEK 0.3053. Following this transaction, Jan Poulsen privately owns 1,647,815 shares and through 100% owned companies an additional 40,964,661 shares bringing his total holdings to 42,612,476 shares. His spouse has in the same period purchased 280,000 shares, and she now owns 427,006 shares".
0 · Reply
Pandurotwo
Pandurotwo Sep. 16 at 12:54 PM
$ACIXF As of today the future may well contain an emission of some kind. Even if it happens we cannot avoid headlines like these when Large hospitals, V.A. etc. start ordering in Bulk. Who knows if in 6 month from now we’ll have to adjust to news like this? Goldman and Carnegie initiates investment in Acarix ab with a buy and price target of SEK 20 and 22. Morning Herald: “Stocks with high potential”..Acarix… UKFinancapulse.com: Millionaires buy this stock… Disclaimer. I’m holding on to my shares.
0 · Reply
Latest News on ACIXF
No data available.
Pandurotwo
Pandurotwo Apr. 9 at 7:02 PM
$ACIXF https://iqmediacorp.com/ExternalIframeMedia?mediaID=41fb0f68-a9ca-4f8f-bf3f-3d8597280833&isRM=false&rawMediaType=TV&end=true
0 · Reply
Pandurotwo
Pandurotwo Apr. 9 at 6:59 PM
$ACIXF From LinkedIn Dr. George Chrysant and I sat down with KOKH FOX 25 News, Oklahoma to discuss new research from the American Heart Association, and the implications are far bigger than many realize. By 2050, 6 in 10 U.S. women are projected to have some form of cardiovascular disease. At the same time, rates of diabetes and obesity in women are expected to rise by 67% and 36%, respectively. Even more concerning, cardiovascular disease is accelerating among younger populations, impacting nearly a third of women ages 20–44 and rising sharply among girls. This isn’t just a women’s health issue. It’s a public health issue that affects families, communities, and the future of our healthcare system. Despite being the leading cause of death for women, heart disease is still too often underdiagnosed, especially when symptoms don’t present in typical ways. That gap in awareness, detection, and access to care is something we must address now. At Acarix, we believe earlier insight
1 · Reply
Pandurotwo
Pandurotwo Mar. 29 at 7:17 PM
$ACIXF From the CEO: Great to spend time at #ACC with Ken Nelson, whose experience and perspective continue to be incredibly valuable as we scale Acarix in the U.S. and beyond. What stands out most is the convergence we are seeing across the ecosystem. Conversations with customers, partners, and industry leaders are no longer siloed. Commercial strategy, R&D innovation, and collaborative partnerships are aligning in a very real way. From a commercial standpoint, there is growing clarity around how #CADScor can be integrated into clinical workflows to drive better patient outcomes while reducing unnecessary testing. That alignment is critical as we continue to expand access and….
2 · Reply
Pandurotwo
Pandurotwo Mar. 13 at 11:56 AM
$ACIXF Article from 10th March 2026. European Heart Journal. See attached. https://academic.oup.com/ehjimp/advance-article/doi/10.1093/ehjimp/qyag043/8512988 Article Navigation JOURNAL ARTICLE ACCEPTED MANUSCRIPT Diagnostic performance of combined biomarkers and phonocardiography versus the 2024 ESC risk factor-weighted clinical likelihood model for detecting coronary artery disease
0 · Reply
Pandurotwo
Pandurotwo Oct. 9 at 3:39 PM
$ACIXF Today Oct. 9th: NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB Qoute: Proposed agenda Opening of the general meeting and election of chairman of the general meeting Preparation and approval of the voting list Election of one or two persons to verify the minutes Approval of the agenda Determination as to whether the meeting has been duly convened Resolution to change the terms in the Employee Stock Option Program 2025/2029 Closing of the general meeting. Unqoute. Nothing changes for us. In short: "Resolution to change the terms in the Employee Stock Option Program 2025/2029" , " Dilution No change in dilution will arise as a result of the board's proposed amendments.".
0 · Reply
Pandurotwo
Pandurotwo Oct. 8 at 1:28 PM
$ACIXF Good News! When searching the swedish finansiel register the net short position of all outstanding short positions has dropped below the min. reporting limit. (This time the shorters lost money on their inventure, ( approx. 15%)).
0 · Reply
Pandurotwo
Pandurotwo Oct. 7 at 9:53 AM
$ACIXF New reembursement deal in place.
0 · Reply
Pandurotwo
Pandurotwo Oct. 6 at 6:20 PM
$ACIXF The German reimbursement for medical devices with regards to Acarix CADScor will be settled when the 13 members of the Federal Joint Committee have their monthly sitdown on October 16th 11am to 3pm lt in Berlin, Germany. Under TOP 8 , topic): 8.3.2 and 8.3.3 Guideline on Methods of Statutory Health Care: Phonocardiography to rule out coronary heart disease In order to decide on an amendment to the MVV-RL & KHMe-RL directive. At this point I can’t find anything on the amount of reimbursement as there is some variables which the G-BA will uncover on 16th. It is certain though that reimbursement depends on inclusion in specific service catalogues or as assistive devices listed in the Medical Aids Directory.
0 · Reply
Pandurotwo
Pandurotwo Sep. 18 at 6:09 PM
$ACIXF Notice. We know the CEO increased his stock by 1 mill. to 10,904,824 shares and 50,000,000 stock options 10 days ago. 18th Sept.: "Acarix Chairman Jan Poulsen Acquires Shares I the period 15. -- 18. September, Jan Poulsen privately purchased 475,000 shares at an average price of SEK 0.3053. Following this transaction, Jan Poulsen privately owns 1,647,815 shares and through 100% owned companies an additional 40,964,661 shares bringing his total holdings to 42,612,476 shares. His spouse has in the same period purchased 280,000 shares, and she now owns 427,006 shares".
0 · Reply
Pandurotwo
Pandurotwo Sep. 16 at 12:54 PM
$ACIXF As of today the future may well contain an emission of some kind. Even if it happens we cannot avoid headlines like these when Large hospitals, V.A. etc. start ordering in Bulk. Who knows if in 6 month from now we’ll have to adjust to news like this? Goldman and Carnegie initiates investment in Acarix ab with a buy and price target of SEK 20 and 22. Morning Herald: “Stocks with high potential”..Acarix… UKFinancapulse.com: Millionaires buy this stock… Disclaimer. I’m holding on to my shares.
0 · Reply
Pandurotwo
Pandurotwo Jul. 29 at 12:26 PM
$ACIXF Our comment As we have repeatedly emphasised, reimbursement remains a core pillar of the investment case. Monday’s press release, therefore, marks another significant step forward, with a second US payor agreeing to a fixed reimbursement of USD300 for the CADScor System. The first agreement was announced in mid-June 2025 with a regional Third-Party Administrator based in Oklahoma (link to our note). Historically, private payors have tended to align on reimbursement levels and the adoption of fixed reimbursement structures. We therefore believe this development could mark the early stages of a domino effect, with additional private payors likely to follow. The market reacted positively to the press release, with the share now trading around our base case of SEK0.40. We consider this move justified and would not be surprised if the market begins to price in a bull case scenario should positive news flow continue and revenue growth follow.” They keep their estimates…
0 · Reply
Pandurotwo
Pandurotwo Jul. 29 at 7:16 AM
$ACIXF Acarix receives reembursement from the second private payer. https://lnkd.in/dbUG7hUj Qoute:”Acarix CADScor was added at $300 in July to a high-performance provider network to enhance care and cost savings. This Payer provides a Network that services employers and individuals in the Oklahoma, Texas, Ohio, and Louisiana markets which consists of over 500,000 covered lives with 12,000+ Primary Care Physicians, 69.000+ Specialists and 3,000+ Facilities/Ancillaries”. Unqoute.
0 · Reply
Pandurotwo
Pandurotwo Jul. 8 at 2:34 PM
$ACIXF Break through order in the MENA region
0 · Reply
Pandurotwo
Pandurotwo Jul. 7 at 3:31 PM
$ACIXF Global focusing must mean Acarix is satisfied with the way the US market is developing which is good news.
0 · Reply
Pandurotwo
Pandurotwo Jun. 26 at 7:49 AM
$ACIXF Announcement from the CEO:
0 · Reply
Pandurotwo
Pandurotwo Jun. 25 at 9:19 AM
$ACIXF Latest analysis from pharmacoEconomics. Awaiting PM on this as this has great effect on Acarix. Qoute: Results Base case results demonstrated that a CADScor-First strategy was cost saving compared with other noninvasive cardiac tests without a substantial difference in adverse events. Economic results were consistent when coronary artery disease (CAD) prevalence rates were varied from 2 to 30% and across a variety of sensitivity analyses. The overall cost savings were estimated to be $7.3–15.3 million USD per 10,000 patients with low-risk chest pain. Unqoute. https://link.springer.com/article/10.1007/s41669-025-00590-2
0 · Reply
Pandurotwo
Pandurotwo Jun. 16 at 5:17 PM
$ACIXF BINGO !! Acarix: First fixed US reimbursement for CADscor secured Research Note Monday June 16 Redeye endorses today’s news that Acarix has secured a fixed reimbursement of USD300 for the CADScor System. This represents a key milestone in the company’s US commercialisation efforts. Furthermore, we anticipate a potential snowball effect could follow, with additional private payors likely also to provide fixed reimbursement in the near future.
0 · Reply
Pandurotwo
Pandurotwo Apr. 19 at 9:59 AM
$ACIXF Info now that Q1 is to be revealed on Mai 12.. Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind. Full year 2024 results: kr0.072 loss per share (improved from kr0.16 loss in FY 2023). Revenue: kr6.20m (flat on FY 2023). Net loss: kr66.2m (loss narrowed 15% from FY 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. I trust EPS Q1 is close to zero if not positive. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
0 · Reply
Pandurotwo
Pandurotwo Mar. 31 at 9:47 AM
It seems no one is in here thus I'll stop writing myself... $ACIXF
0 · Reply
Pandurotwo
Pandurotwo Mar. 17 at 6:48 PM
$ACIXF CEO buy's stock on 11th and 12th March. 1.2 mill. shares in total.
0 · Reply
Pandurotwo
Pandurotwo Mar. 14 at 9:20 AM
$ACIXF PM ! Acarix Named 2025 Digital Innovation Winner by Global Cardiovascular Awards.
0 · Reply
Pandurotwo
Pandurotwo Mar. 13 at 10:54 PM
$ACIXF From "X" Marlou and Christian Representing Acarix in London on the night of the awards, 13th March 2025.
0 · Reply